FBI-Files
1 주 전
The question is whether the Lenzi drug has any value. When it was sold, the seller or humanigen receiver put a zero value on the patent and it was just part of the bankruptcy process to finalize the bankruptcy case and creditors can no longer make any claims on the 'corporation' like a person. ALL the assets have been SOLD for 'fair market' value.
If lenzi has value, then former owners can put a claim on the profits of the drug. in civil case. not in a bankrupt case. anyways, the 'stolen money' that former management alleddged 'stole'd is gone and hidden in layers of shell companies in another country in switzerland. and FBI or SEC isn't not going to spend 1 million in getting any of the money. SEC may ban or give fines, but they won't get a dime of any fines, and no jail time. They've been given permission to steal by the SEC or gov't
Now if the assets were sold BELOW value it's called fraud and embezzlement. As such those assets sold is considered STOLEN assets. An legal common laws says buyers of 'stolen' assets don't have legal ownership of the assets if they former owner has a claim on it. Which the buyer of any 'stolen' asset or asset has a lien on it must be careful, hence lawyers and lein checks are done when buying a car and house. And that has risk but rare that a lien check can be fraudulent and why people pay $10,000 to lawyers to ensure the sale is 'clean' and no leins. or the asset is 'stolen'
There was very rare situation where a lottery ticket was purchased with a 'stolen credit card'
https://www.ctvnews.ca/world/article/thieves-bought-a-winning-lottery-ticket-with-a-stolen-credit-card-its-owner-has-offered-to-split-the-jackpot/
it was $500,000 USD winning ,the theif was a homeless man and bought a winning ticket with stolen credit card and won. its rarer than winning thee jackpot more like 1 in 100 million chance..winning a jackpot is one in 13 million right
the theif doesn't is not legally entitled to any winnings. you never 'own' a stolen asset.
cowtown jay
1 주 전
On the X.com platform, a drug discovery company called BioSymetrics is featured as having partnered with Humanigen. Of note to me is that Northwell Health is also mentioned as a BioSymetrics partner. Northwell has a group of 18 nurses that formed a choir to uplift their fellow nurses after the onset of the Covid tragedy, and I was touched by their performances, such as seen here,
But, on a deeper level, the FDA granted IND Authorization to use Humanigen's Lenzilumab to treat Covid just weeks after the pandemic hit our shores. I've always thought this was because of the early-stage trials Humanigen had done on using lenz as a cancer treatment. However, I see now that Northwell/BioSymetrics reported, "Prior to the pandemic we were actively working on Acute Respiratory Distress Syndrome (ARDS) in partnership with Northwell Health (the largest hospital network in New York), which positioned us well to expand into COVID-ARDS as it became the highest cause of mortality in COVID-19 patients."
https://www.biosymetrics.com/blog/blog-interview-with-vp-of-data-science-research-on-covid-19-studies-with-humanigen
On a deeper level, still, BioSymetrics' Dr. Catterson noted in the linked interview, "SWOV is an endpoint which captures not only survival, but also quality of life of the surviving patients, and is therefore a strong marker of effectiveness." And it is this aspect of lenzilumab's safety and efficacy that I hope will be particularly focused on, as I think it will be in sharp contrast to Serious Adverse Events and other quality of life measurements observed in other treatment options.
cowtown jay
1 주 전
Today is the deadline for up to 80,000 HHS employees to opt-in to a $25,000 buyout.
"The email was sent to workers across multiple agencies, including the U.S. Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH) and the U.S. Food and Drug Administration (FDA)."
https://www.powershealth.org/about-us/newsroom/health-library/2025/03/11/hhs-employees-offered-as-much-as-25k-to-leave-jobs#:~:text=TUESDAY%2C%20March%2011%2C%202025%20(,many%20of%20its%2080%2C000%20employees.
When I saw that announced, it gave me pause to further consider my course. Perhaps my effort should likely be directed to the SEC Commissioners, assuming Trump's new SEC Chair nominee, Paul Atkins, is better than his first term nomination of Jay Clayton, who was shocked to learn about naked shorting. But I am glad to see SEC investigation decisions taken out of the SEC Enforcement's Divisions hands. This is especially true since the SEC's investigation into Humanigen was totally without warrant to commence.
https://www.paulhastings.com/insights/client-alerts/sec-reportedly-requiring-enforcement-staff-to-seek-commission-approval-for-formal-orders-of-investigation
As of now, I think we're done, and that management has accomplished all of their objectives on our behalf, and there is no reason to pick a fight for us to be justly rewarded.
SorcererGuru44
2 주 전
To fully answer your question:
This is paying for the services incured by receiver Geoff Winkler (AFS) and Greenberg Traurig.
The fees are in a table broken down with the following info:
Applicant | Total Fees | Interim Payment Requested (Fees) | Expenses | Interim Payment Requested (Expenses)
Receiver/AFS | $37,453.50 | $29,962.80 | $1,724.38 | $1,724.38
Greenberg T | $2,683.02 | $2,146.41 | $0 | $0
There are more detailed breakdowns available throughout as well, but that is the totals.The most interesting bit was probably this:
"During the Application Period, and with assistance of counsel, the
Receiver and the AFS team made progress on elements of Estate administration,
including further analysis of assets; continued review of account records and
auditing needs; communication with Mr. Chappell and/or his counsel regarding
estate assets; communication with financial institutions and other holding assets and
evaluation of next steps including working with Goldman Sachs on a plan to
liquidate the remaining positions held in the two accounts; communication with
investors; continue process of winding down the business and liquidation of assets;
handling of tax issues; retention of auditor for Black Horse Capital, LP., Black Horse
Capital Master Fund, Ltd., and Black Horse Capital Offshore and work with same;
processing expenses and approved accounts payable; and preparation of quarterly
report and requisite filings."
Hope this provides the insight you were after 🍻
SorcererGuru44
2 주 전
Friendly reminder to all those visiting: Humanigen no longer exists, has no IP, their shares have been cancelled by FINRA, and thus do not exist. Your previous shares will remain visible in your trading accounts until the bankruptcy has concluded.
Pay no attention to speculation, disinformation around trials, partnerships, and like.
Anyone searching for information can find all relevant material surrounding the bankruptcy and sale of assets here: https://dm.epiq11.com/case/humanigen/info
Information surrounding the SEC vs. Dale can be found on PACER & Pacer Monitor
I've seen a couple posts asking me about document paywalls and what's behind them. If I have some free time I will check tomorrow.
That is all. Cheers 👋
cowtown jay
3 주 전
The Liquidating Trust has until July 7th to object to claims, unless he asks for an extension. I'm interested in how claims to the IP may have been affected by the amended Asset Purchase Agreement, if at all. Has a reverse merger or consolidation come into play?
Docket List: https://dm.epiq11.com/case/humanigen/dockets
I drilled down to the bone in SpongeTech's bankruptcy case, and in regards to who was Naked Shorting the stock. I'm totally shut out of those areas in Humanigen's case.
I'm looking forward to seeing how a BLA may have progressed here, particularly in terms of what may have been learned regarding covid pneumonia reinfection rates in lenz-treated patients, as well as presentations of covid-related indications and mortality rates.
cowtown jay
3 주 전
No, I can't, dlog, and I've looked. I think my belief that lenz is the miracle covid vaccine enhancement actually precedes any patents that supports my belief. I remember saying that I would have taken the Novavax covid vaccine, just to have a reason to take lenz as a follow-up chaser. I just knew, at that point in time, that doing that would have saved countless, millions, losses of life. Those preventable excess deaths continue to this day. And my pro-Novavax bias remains strong today, but with substantiation now for that belief in the form of the NVAX EUA.
But, can you name any licensed covid vaccine in the US that is not an mRNA vaccine? There's only one, the Novavax vaccine. And Sanofi has disclosed that they are using that vaccine in their Covid Influenza Combination (CIC) vaccine. Sanofi conservatively (inaccurately) estimates that this CIC vaccine will result in a 56% increase in demand for their existing flu vaccine. I think that is under-stated, and in terms of the covid component of this CIC vaccine, it will be 100% of the US covid market, as Pfizer and Moderna will lose their EUA authorizations, once the triumvirate of Humanigen/Sanofi/Novavax have attained their full regulatory approvals.
And I think these pending approvals are the reason we see the CDC and the FDA cancel their previously scheduled vaccine advisory committee meetings, since lenz is variant agnostic.
Don't forget just how miraculous lenz has proven to be in CAR-T, which appears to have reduced Gracell's processing time from ~16 days per patient treatment compounding time, to
cowtown jay
4 주 전
Hi, eb!
In college, I discovered that my interests were in political science and economics. I wasn't particularly happy to make that discovery, because I couldn't imagine a more frustrating career choice than being a political economist. So I never tried to go to law school. But I could not shake my motivation to fight against the abuse of discretionary authority by unelected government bureaucrats. I was honored to have been asked by SpongeTech's bankruptcy trustee to become the Estate Representative for shareholders in that company. In that capacity, I subpoenaed Electronic Blue Sheet trading records from FINRA which showed the continuous Naked Short selling of tens of millions of shares in that company everyday, despite FTD short sell restrictions, all the while until trading was finally halted. That effort proved for naught, as the bankruptcy judge recognized that shareholders had a case, but he could not see how the naked short selling impacted the company.
In Humanigen's case, the SEC has largely hidden their abuse of discretionary authority, since the case was sealed. But, Humanigen being a biotech, there is a plethora of other government agencies shown abusing their discretionary authority, such as NIAID, the NIH, the FDA, the CDC, the DOJ, and still, the SEC, to an extent that is known. The most promising appointment in this new Administration, for my purposes. is that of RFK, Jr., as the head of the HHS. I hope he will expose the real toll of the harm our present course is extracting by our national covid response, to include the significant number of excess deaths being reported since the pandemic.
Somewhat ironically, a research report titled 'Mortality Trends Among Early Adults in the United States, 1999-2023,' was just published by the JAMA Network. I say it's ironic, because it was funded, in part, by a grant established by Bobby's Aunt Ethel's foundation.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2829783
The Report notes, "Early adult excess mortality was 34.6% higher than expected in 2019 and then further accelerated during the COVID-19 pandemic. In 2021, all-cause excess mortality was nearly 3 times what it had been in 2019 (116.2 vs 41.7 deaths per 100?000 population). In 2023, excess mortality decreased, but only to approximately midway between its 2019 and 2021 levels (79.1 deaths per 100?000 population). As a result, early adult mortality was 70.0% higher in 2023 than it would have been had pre-2011 trends continued, reflecting 71?124 excess deaths."
I've previously linked mortality data from other studies that are pretty much in-line, showing excess deaths that are >80% higher than expected, That's why I believe we are seeing tens of millions of preventable deaths. I think Lenzilumab could help restore the immune system in these post pandemic 1, and in pre-pandemic 2 populations.
cowtown jay
4 주 전
"No human would still follow a stock 1 year (after) bankruptcy etc."
One year? Try 15 years, and counting. In fact, the SEC recently filed an Admin Proceeding against SpongeTech relating to charges and a bankruptcy that were filed in 2010. I long awaited this latest filing, and was thrilled to see it released at this point in the process of the Humanigen proceedings. Due to the SEC hiding behind a sealed civil case here, I was not able to prove Naked Shorting in this case, as I did with SpongeTech.
https://www.sec.gov/files/litigation/admin/2024/34-101539.pdf
Nevertheless, if our float represented 229% of our Outstanding Shares, those loaned shares represent a significant value to the company, should management announce a second recall of their loaned shares, as we saw in our predecessor company, Kalobios.
cowtown jay
1 월 전
In the trial investigators' video presentation, Dale mentioned that a certain KOL (Key Opinion Leader), asked them to detail the treatment outcomes for Black and African American patients. I wonder if Alondra Nelson asked the White House's Office of Science and Technology, (which she was subsequently chosen to Direct), or NIH Director Francis Collins, to request that information. I'd also like to know if she knew the NIH trial was designed to fail, or that it appears that half of the Black and African American patients were dropped from the trial reporting.
"AI Overview
Learn more
https://upload.wikimedia.org/wikipedia/commons/a/a0/Francis_Collins_official_portrait.jpg
Dr. Francis Collins served as the 16th director of the National Institutes of Health (NIH) from August 17, 2009 until December 19, 2021. His 12-year tenure was the longest of any presidentially appointed NIH director."
And yes, I think Kennedy will be surprised by the government's role in this deadly charade to keep Humanigen's lenzilumab off the covid treatment guidelines.
cowtown jay
1 월 전
Hello, Thenatsy
Thank you for your interest in my posts. I'm certainly not able to speak with authority regarding, "... what's happening with the company and our shares..." I can only draw conclusions about what I observe.
For instance, and in regards to your question, Humanigen features the progress they made in treating CMML on their corporate X.com site.
https://x.com/humanigen
However, Humanigen does not appear to own the Intellectual Property rights to treat that indication. Taran Therapeutics and the University of Adelaide filed the patent application AFTER the bankruptcy case was initiated in January 2024.
https://patents.justia.com/assignee/taran-therapeutics-inc
I think the bankruptcy court judge likely had to approve the assignment of that patent right as part of the amended Asset Purchase Agreement he approved before the bankruptcy case was resolved. I also believe that Humanigen, Inc's shares were transferred to Humanigen Australia as part of this deal, which will see us merge with Taran, reuniting the share structure with the IP.
That consolidation, in itself, does not produce revenue or meet any financial obligations Humanigen, Inc., may yet be required to meet. This tells me that the bankruptcy court judge was provided assurance that the unsecured debt will be, or has been, met or assumed by Taran, who appears to be anticipating approval to treat CMML from Australia's TGA regulatory agency.
Hot Features
프리미엄
무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
shajandr
2 주 전
DTGoody
4 주 전
